Skip to main content

and
  1. Article

    Open Access

    Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis

    To compare the efficacy, safety and effects on quality of life of different ALK-inhibitors for global and Asian patients with advanced ALK-positive non-small-cell lung cancer (NSCLC).

    Mingye Zhao, Taihang Shao, Hanqiao Shao, Caicun Zhou, Wenxi Tang in BMC Cancer (2024)